Clinical Trial Update: A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib in adults with advanced, low-proliferative neuroendocrine neoplasms (NET G3), including neuroendocrine tumors and neuroend…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendostrine Tumor

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Karsten Gavenis | Conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING